


Macroeconomic Commentary

After a strong start, public markets reversed sharply during the first quarter of 2018, with the S&P 500 ending down 1.2%, its first quarterly decline since 2015. The quick reversal and sudden increase in perceived market volatility were caused by a number of developments, including the departures of Gary Cohn and other prominent U.S. Cabinet members, a new Federal Reserve Chairman, the ongoing Mueller investigation, expectations for higher inflation, trade tensions with China, and, more recently, concerns regarding privacy and data usage by Facebook and other technology companies. Amid these concerns, it is worth noting the global economic outlook continues to appear attractive, with strong earnings growth expected across a number of sectors and geographies. In addition, last year’s U.S. tax reform may provide fuel for further growth in the near-term as the impact of the legislation has yet to flow through to the broader economy in a material way.

Global Private Equity Commentary

Private equity fundraising, transaction volume, and exit activity is off to a relatively slow start in 2018, but planned fundraising, announced but not yet closed deals, and potential shifts in the M&A market could accelerate activity over the coming months. U.S. private equity fundraising declined by 34% on a year-over-year basis, with only \$37 billion raised by 55 funds, compared to \$56 billion raised by 57 funds during the same



Source: Pitchbook

period in 2017. The largest U.S. fund raised during the quarter was American Securities Partners VIII, which closed on \$7 billion. It should be noted that Abbott is aware of a number of \$10 billion-plus funds coming to market in the near-term, which is likely to put 2018 fundraising back on pace with that of the recent past. In contrast, European fundraising activity surged in Q1, with 15 funds raising a combined €29 billion, a 54% increase by assets raised from the same period last year. European mega buyout funds accounted for more than 75% of total capital raised during the quarter, with EQT VIII (€11 billion), BC European Capital X (€7 billion), and PAI Europe VII (€5 billion) leading the charge.


In the U.S., new investment activity declined significantly year-over-year, highlighting general partner cautiousness in an elevated valuation environment. The first quarter of 2018 saw 881 investments close with an aggregate value of \$77 billion, a 42% decline from Q1 2017 in terms of deal value. In fact, Q1 2018 marked the first quarter since 2013 that total U.S. deal volume did not reach at least \$100 billion. Perhaps not surprising in this market, a majority of last quarter’s deal activity came from add-on acquisitions, which generally allow private equity firms to average down their platform acquisition multiples and realize synergies. European investment activity declined from Q1 2017 levels, with €51 billion invested across 553 deals, compared to €83 billion in 554 deals during the same period last year. As referenced above, however, there were a number of

deals across Europe announced in Q4 2017 and Q1 2018 that have yet to close. Reports indicate these deals could total nearly €12 billion, suggesting European firms were potentially more active in Q1 2017 than the current statistics indicate.

Private equity-backed exits in the U.S. totaled \$37 billion across 196 transactions in Q1 2018, a 28% decline by number and 10% decline in value when compared to Q1 2017 exit volume. Corporate acquisitions dominated the exit environment, comprising 61% of exit value, a level that has remained fairly stable over the recent past. At the same time, European exit activity slowed significantly, as total transaction value and number of exits fell to their lowest levels in four years. However, as alluded to above, reports suggest that European private equity-backed exit activity may pick up over the course of 2018, as eight €1 billion-plus exits were announced but have not yet closed.

Global Venture Capital Commentary

U.S. VC fundraising was flat during the first quarter compared to Q1 2017, as 54 funds raised nearly \$8 billion, compared to 58 funds that raised almost the identical amount during the same time period last year. The emergence of several micro funds, or vehicles with total commitments of \$50 million or less, have driven median fund sizes down recently, although it should be noted that a number firms are expected to raise \$1 billion plus funds in the near future. Overall, limited partner demand for venture capital remains robust and 2018 is projected to be a strong year in terms of capital raising for the industry.



Source: Pitchbook

Capital deployment by venture capitalists remained robust in Q1 2018, as firms invested an aggregate \$28 billion into 1,693 investments across all stages, representing a 67% year-over-year increase in capital invested. In fact, on a quarterly basis more capital was deployed in Q1 2018 than in any quarter in the past decade; the previous high was set in Q2 2016 when \$24 billion was deployed. Large financing rounds into Unicorns, Lyft and Uber in particular, contributed to the quarter’s record-breaking amount of invested capital, following a recent trend.

U.S. VC exit activity declined 52% (based on exit value) since the same period last year, with 188 exits totaling just north of \$8 billion, compared with last year’s 233 exits, which totaled more than \$17 billion. This development is likely attributed to larger private financing rounds led by later stage investors highlighted previously. As a result of companies staying private longer, venture-backed IPOs remained limited, while secondary sales have increasingly emerged as a source of liquidity for early and mid-stage investors. It is worth noting that with only one quarter’s worth of data, extrapolating any trends may be premature, but the decline in exit value in the VC space is a data point worth keeping an eye on moving forward.

First Quarter 2018 Private Equity Market Overview

IMPORTANT INFORMATION

Past performance is not a guide to future results and is not indicative of expected realized returns. The views expressed and information provided are as of the date posted unless otherwise indicated on a particular page or chart and are subject to change, update, revision, verification and amendment, materially or otherwise, without notice, as market or other conditions change. Since these conditions can change frequently, there can be no assurance that the terms and trends described herein will continue or that any forecasts are accurate. In addition, certain of the statements contained in this presentation may be statements of future expectations and other forward-looking statements that are based on the current views and assumptions of Abbott Capital Management, LLC ("Abbott") and involve known and unknown risks and uncertainties (including those discussed below and in Abbott's Form ADV, Part 2a., available on the SEC's website at www.adviserinfo.sec.gov) that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These statements may be forward-looking by reason of context or identified by words such as "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential or continue" and other similar expressions. Neither Abbott, its affiliates, nor any of Abbott's or its affiliates' respective advisers, members, directors, officers, partners, agents, representatives or employees or any other person (collectively "Abbott Entities") is under any obligation to update or keep current the information contained in this document.

This presentation contains information from third party sources which Abbott has not verified. No representation or warranty, express or implied, is given by or on behalf of the Abbott Entities as to the accuracy, fairness, correctness or completeness of the information or opinions contained in this presentation and no liability whatsoever (in negligence or otherwise) is accepted by the Abbott Entities for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents, or otherwise arising in connection therewith.

Performance Information: Where Abbott performance returns have been included in this presentation, Abbott has included herein important information relating to the calculation of these returns as well as other pertinent performance related definitions.

References to market or composite indices, benchmarks or other measures of relative market performance over a specified period of time are provided for your information only and do not imply that the funds sponsored by Abbott (the "Abbott Funds") and Abbott's managed account clients (collectively with the Abbott Funds, "Abbott Clients") will achieve returns, volatility or results similar to the index, or that these are appropriate benchmarks to be used for comparison for a private equity investment. The market volatility, liquidity and other characteristics of private equity investments are materially different from publicly-traded securities. In addition, the composite of the index may not reflect the manner in which the Abbott Client portfolio is constructed in relation to expected or achieved returns, portfolio guidelines, restrictions, sectors, correlations or volatility, all of which are subject to change over time. The index returns will generally reflect the reinvestment of dividends, if any, but do not reflect the deduction of any fees or expenses which would reduce returns. An investor cannot invest directly in an index.

All investments are subject to risk, including the loss of the principal amount invested. Private equity related risks include, among others: those associated with leverage, illiquidity and restrictions on transferability and resale of the investment and the speculative nature of private equity investments in general. Fund of fund risks include dependence on the performance of underlying managers, Abbott's ability to allocate assets incurred at the Abbott Client and underlying portfolio fund levels. Exchange rate fluctuations may affect returns. Diversification will not guarantee profitability or protection against loss. There is no assurance that an Abbott Client's objective will be attained. Performance may be volatile and the value of an investment(s) may fluctuate. Please refer to Abbott's Form ADV, Part 2a for additional risk disclosures.

This presentation is for informational purposes only and is not an offer or a solicitation to subscribe for any fund and does not constitute investment, legal, regulatory, business, tax, financial, accounting or other advice or a recommendation regarding any securities of Abbott, of any fund or vehicle managed by Abbott, or of any other issuer of securities. Interests in the Abbott Funds have not been and will not be registered under the U.S. Securities Act of 1933, as amended, any U.S. State securities laws or the laws of any non-US Jurisdiction. None of the Abbott Funds are registered as an Investment Company under the U.S. Investment Company Act of 1940, as amended nor is it expected that they will be in the future. Interests in the Abbott Funds have not been approved or disapproved by The U.S. Securities and Exchange Commission or by any securities regulatory authority of any U.S. State or non-U.S. jurisdiction and neither the SEC nor any such authority has passed upon the accuracy or adequacy of this communication or the merits of Abbott or any Abbott Fund, nor is it intended that the SEC or any such authority will do so. Investment in the Abbott Funds may not be suitable for all investors; investors should carefully consider risks and other information and consult their professional advisers regarding suitability, legal, tax and economic consequences of an investment.

To UK Investors: If communicated by Abbott Capital (Europe), Ltd, this presentation may be distributed to, or directed at, only the following persons: (i) persons who are "investment professionals" as defined in article 14(5) of the FSMA 2000 (Promotions of Collective Investment Schemes)(Exemptions) Order 2001 (the "PCISE Order"); (ii) persons who are high net worth companies, unincorporated associations, partnerships or trusts falling within any of the categories of persons described in article 22 of the PCISE Order; and (iii) any other person to whom it may otherwise lawfully be made in accordance with the PCISE Order or rule 4.12.4 of the Conduct of Business Sourcebook of the FCA Handbook (all such persons together being referred to as "Relevant Persons"). Persons who are not Relevant Persons must not act on or rely on this presentation or any of its contents. Any investment or investment activity to which this presentation relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Recipients must not distribute, publish, reproduce or disclose this material, in whole or in part, to any other person. Abbott Capital (Europe), Ltd, is authorized and regulated by the UK Financial Conduct Authority.

If communicated by Abbott Capital Management, LLC, this presentation may be distributed to, or directed at, only the following persons: (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FP Order"), (ii) high-net-worth entities falling within Article 49(2) of the FP Order, and (iii) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "FPO Relevant Persons"). Persons who are not FPO Relevant Persons must not act on or rely on this presentation or any of its contents. Any investment or investment activity to which this presentation relates is available only to FPO Relevant Persons and will be engaged in only with FPO Relevant Persons. Recipients must not distribute, publish, reproduce or disclose this presentation, in whole or in part, to any other person.

Copyright© Abbott Capital Management, LLC 2018. All rights reserved. This presentation is proprietary and may not to be reproduced, transferred or distributed in any form without prior written permission from Abbott. It is delivered on an "as is" basis without warranty or liability. All individual charts, graphs and other elements contained within the information are also copyrighted works and may be owned by a party other than Abbott. By accepting the information, you agree to abide by all applicable copyright and other laws, as well as any additional copyright notices or restrictions contained in the information.